Effective Dwell Time of Peripheral Vascular Access Device in Patients Receiving Continuous Intravenous Heparin Therapy

2.50
Hdl Handle:
http://hdl.handle.net/10755/152672
Type:
Presentation
Title:
Effective Dwell Time of Peripheral Vascular Access Device in Patients Receiving Continuous Intravenous Heparin Therapy
Abstract:
Effective Dwell Time of Peripheral Vascular Access Device in Patients Receiving Continuous Intravenous Heparin Therapy
Conference Sponsor:Sigma Theta Tau International
Conference Year:2003
Conference Date:July 10-12, 2003
Author:Adams, Jeanette, RN, PhD, CRNI, CS
P.I. Institution Name:Consultant
Objective: The purpose of this study was to investigate the dwell time and the incidence of complications for short, peripheral venous catheters (SPVC) in patients who received continuous heparin infusion therapy.<P> Design: A descriptive, retrospective design was used.<P> Population, Sample, Setting, Years: Adult patients in an acute care facility comprised the population. The sample consisted of 80 patients who were admitted to an urban hospital care system. The hospital had an infusion team consisting of registered nurses who were responsible for the placement of vascular access devices. Criteria for a convenience sample included: 1) continuous intravenous heparin therapy for a minimum of five days; and, 2) placement of a SPVC in the upper extremity by a nurse from the infusion team.<P> Variables: The focus of this study was on the incidence of complications as it related to the dwell time of SPVC.<P> Methods: A retrospective review was conducted on the dwell time of the SPVC. Documentation was reviewed to ascertain the site condition on a daily basis and the day and time the initial placement was restarted. Chi square analysis was used to determine statistical significance.<P> Findings: Chi square analysis revealed statistical significance that there was no difference with complications in 72 hour dwell time and 120 hour dwell time.<P> Conclusions: It was concluded that patients receiving continuous intravenous heparin therapy may extend their dwell time of SPVC to 120 hours without increased risk of complications.<P> Implications: A patient population was identified that may extend vascular access dwell time to 120 hours without increased risk of complication. This is the only evidence based research study found that analyzes a specific population. As standards of practice and guidelines are expanded for vascular access dwell times, research must be employed to determine the safety and efficacy for patient outcomes.<P> <P> <!--Abstract 13690 modified by 205.188.208.101 on 11-5-2002--></P></P></P></P></P></P></P></P></P>
Repository Posting Date:
26-Oct-2011
Date of Publication:
10-Jul-2003
Sponsors:
Sigma Theta Tau International

Full metadata record

DC FieldValue Language
dc.typePresentationen_GB
dc.titleEffective Dwell Time of Peripheral Vascular Access Device in Patients Receiving Continuous Intravenous Heparin Therapyen_GB
dc.identifier.urihttp://hdl.handle.net/10755/152672-
dc.description.abstract<table><tr><td colspan="2" class="item-title">Effective Dwell Time of Peripheral Vascular Access Device in Patients Receiving Continuous Intravenous Heparin Therapy</td></tr><tr class="item-sponsor"><td class="label">Conference Sponsor:</td><td class="value">Sigma Theta Tau International</td></tr><tr class="item-year"><td class="label">Conference Year:</td><td class="value">2003</td></tr><tr class="item-conference-date"><td class="label">Conference Date:</td><td class="value">July 10-12, 2003</td></tr><tr class="item-author"><td class="label">Author:</td><td class="value">Adams, Jeanette, RN, PhD, CRNI, CS</td></tr><tr class="item-institute"><td class="label">P.I. Institution Name:</td><td class="value">Consultant</td></tr><tr class="item-email"><td class="label">Email:</td><td class="value">jadamsphd@aol.com</td></tr><tr><td colspan="2" class="item-abstract">Objective: The purpose of this study was to investigate the dwell time and the incidence of complications for short, peripheral venous catheters (SPVC) in patients who received continuous heparin infusion therapy.&lt;P&gt; Design: A descriptive, retrospective design was used.&lt;P&gt; Population, Sample, Setting, Years: Adult patients in an acute care facility comprised the population. The sample consisted of 80 patients who were admitted to an urban hospital care system. The hospital had an infusion team consisting of registered nurses who were responsible for the placement of vascular access devices. Criteria for a convenience sample included: 1) continuous intravenous heparin therapy for a minimum of five days; and, 2) placement of a SPVC in the upper extremity by a nurse from the infusion team.&lt;P&gt; Variables: The focus of this study was on the incidence of complications as it related to the dwell time of SPVC.&lt;P&gt; Methods: A retrospective review was conducted on the dwell time of the SPVC. Documentation was reviewed to ascertain the site condition on a daily basis and the day and time the initial placement was restarted. Chi square analysis was used to determine statistical significance.&lt;P&gt; Findings: Chi square analysis revealed statistical significance that there was no difference with complications in 72 hour dwell time and 120 hour dwell time.&lt;P&gt; Conclusions: It was concluded that patients receiving continuous intravenous heparin therapy may extend their dwell time of SPVC to 120 hours without increased risk of complications.&lt;P&gt; Implications: A patient population was identified that may extend vascular access dwell time to 120 hours without increased risk of complication. This is the only evidence based research study found that analyzes a specific population. As standards of practice and guidelines are expanded for vascular access dwell times, research must be employed to determine the safety and efficacy for patient outcomes.&lt;P&gt; &lt;P&gt; &lt;!--Abstract 13690 modified by 205.188.208.101 on 11-5-2002--&gt;&lt;/P&gt;&lt;/P&gt;&lt;/P&gt;&lt;/P&gt;&lt;/P&gt;&lt;/P&gt;&lt;/P&gt;&lt;/P&gt;&lt;/P&gt;</td></tr></table>en_GB
dc.date.available2011-10-26T11:45:16Z-
dc.date.issued2003-07-10en_GB
dc.date.accessioned2011-10-26T11:45:16Z-
dc.description.sponsorshipSigma Theta Tau Internationalen_GB
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.